Logo
 

Cardiovascular precision medecine

The SMART-data initiative represents an extraordinary opportunity for the Université de Montréal (UdeM) and its affiliated research institutes and hospitals to capitalize on massive strategic investments in cutting-edge interdisciplinary research leading to the present precision medicine project. The project, which is an integral part of UdeM strategic priority “From Data do Action In Health”, aims to realize a true paradigm change in cardiovascular precision medicine through data science. With IVADO, UdeM has positioned itself as a leader in big data amongst a small group of trailblazing academic institutions around the world and is now committed to a concerted long-term strategy to apply data science expertise to health and life sciences research. Building on massive investment ($130M) from the Canada First Excellence Research Fund in data science research and its applications to various areas including health, SMART-data will leverage UdeM’s critical mass of talent and multidisciplinary and complementary expertise, cutting-edge infrastructure, quality “–omics” assets, and previous breakthrough discoveries to fundamentally redefine how cardiovascular research is conducted and to translate this effort in clinical practice. Through SMART-data’s Artificial Intelligence and Deep Learning-driven innovation ecosystem, this initiative will lead the development and implementation of novel innovation pathways in cardiovascular diagnostic and treatment.

Researcher Portrait

Jean-Claude Tardif

Jean-Claude Tardif, Professeur titulaire, Faculté de médecine - Département de médecine Jean-Claude Tardif is the Director of the Montreal Heart Institute Research Centre and a full professor of medicine at Université de Montréal. He has published over 700 articles and research abstracts in major scientific journals, such as: The New England Journal of Medicine, the Journal of the American Medical Association, The Lancet, Circulation, the Journal of the American College of Cardiology, Nature Genetics, the British Journal of Pharmacology, and Cardiovascular Research.

Dr. Tardif and his team also created the Beaulieu-Saucier Pharmacogenomics Centre and the Centre of Excellence in Personalized Medicine (Cepmed), which receives ongoing support from multiple pharmaceutical and biotech companies.

To know more

An Tang

An Tang, Professeur agrégé, Faculté de médecine - Département de radiologie The principals reserach interests of An Tang was : the development, validation and clinical translation of imaging-based biomarkers of chronic liver disease. Modalities: magnetic resonance imaging (MRI), computed tomography (CT), ultrasound (US), elastography. Pathologies: chronic liver disease, steatosis, steatohepatitis, liver fibrosis, hepatocellular carcinoma (HCC).



To know more

Marie-Pierre Dubé

Marie-Pierre Dubé, Professeure agrégée, École de santé publique - Département de médecine sociale et préventive Dr. Marie-Pierre Dubé directs the Beaulieu-Saucier Pharmacogenomics Centre at the Montreal Heart Institute (MHI). She is also a researcher at the MHI, where she founded the StatGen Statistical Genetics Research Group.

Dr. Dubé has written over 80 articles that have appeared in specialized journals and has also authored book chapters and patents. She has been involved in a number of pharmacogenomics studies, and she is the principal investigator of a large-scale prospective observational study on the pharmacogenomics of anticoagulant therapy funded by the CIHR and Cepmed.

To know more

Claude Perreault

Claude Perreault, Professeur titulaire, Faculté de médecine - Département de médecine Claude Perreault and his team study T lymphocytes, cells that govern the function of the immune system in order to better understanding and improve the function of the immune system.

More specifically, they are trying to discover i) why the thymus is the sole organ that is able to support T-cell development, ii) how T lymphocytes are educated in the thymus and learn to distinguish self from non-self, and finally iii) how T lymphocytes can recognize cancer cells and how one can increase the anti-tumour activity of T lymphocytes.

To know more

News

Ottawa gives $15.7M for health R&D
Money from the Strategic Investment Fund for Post-Secondary Institutions will help both Maisonneuve-Rosemont Hospital and the Montreal Heart Institute expand their operations.
udemnouvelles | May 29 2017

Do you really have high blood pressure?
If family doctors got rid of their antiquated tensiometers and started using electronic devices instead, they'd make fewer misdiagnoses of hypertension, a medicial sociologist says.
udemnouvelles | May 27 2017

Mortality and heart disease: you don’t have to be an athlete to reduce the risk factors
A new study shows that even low physical fitness is sufficient to produce a preventive effect on most of the risk factors that affect people with cardiovascular disease.
udemnouvelles| October 21 2016

A Biomarker for Diagnosing Pulmonary Hypertension
A clinical study demonstrating the safety of the PulmoBind biomarker and the ability of the PulmoBind tomography (SPECT) scan to clearly show abnormal results in patients with pulmonary hypertension.
udemnouvlles | 16 juin 2015


 

For more information, see the articles about cardiology